Unless otherwise noted, speakers have nothing to disclose.

Moderators

Brent Keeling, MD
Disclosure: AngioDynamics, Inc.: Advisory Board (Ongoing), Consultant (Ongoing); Penumbra, Inc.: Advisory Board (Ongoing)

Amy Hackmann, MD
Disclosure: Medtronic: Advisory Board (Ongoing), Speaker (Ongoing); Abbott Inc.: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)

Presentations

1. Introduction and Overview of PERT Format
   Brent Keeling, MD
   Disclosure: AngioDynamics, Inc.: Advisory Board (Ongoing), Consultant (Ongoing); Penumbra, Inc.: Advisory Board (Ongoing)
    
2. Case 1: High Risk PE
   Elizabeth Norton, MD
    
3. Why Thrombolytics or Transcatheter?
   Minhaj S. Khaja, MD, MBA
   Disclosure: Boston Scientific: Advisory Board (Ongoing), Non-compensated advisory board member (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Medtronic: Advisory Board (Ongoing), Non-compensated advisory board member (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Penumbra: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)
    
4. Why ECMO?
   Jordan R.H Hoffman, MD
    
5. Why Surgical Embolectomy?
   Joshua Goldberg, MD
    
6. PERT Team Discussion and Q&A
    
7. Case 2: PE Treated with Thrombolytics at OSH
   Asher Weisberg, MD
    
8. PERT Team Discussion and Q&A